Aspen Group Stock

Aspen Group ROE

The Return on Equity (ROE) of Aspen Group (APZ.AX) as of Aug 8, 2026 is 10.46 %. In the previous year, Return on Equity (ROE) was 11.17 % — a change of -6.40% (lower).

ROE

10.46 %

YoY

-6.40%

Last updated:

In 2026, Aspen Group's return on equity (ROE) was 10.46 %, a -6.40% increase from the 11.17 % ROE in the previous year.

Access this data via the Eulerpool API

Aspen Group Stock analysis

What does Aspen Group do? Aspen Group Ltd is a globally active pharmaceutical company headquartered in Durban, South Africa. The company's history dates back to 1850, when the first pharmacy was opened by a man named William Charles in Durban. In 1997, Aspen Group Ltd was founded, which continued William Charles' business and expanded strongly in the following years. Aspen's business model is based on the acquisition of pharmaceutical companies and their products, as well as the production of generics and branded drugs. The company operates worldwide and has offices in over 50 countries. Aspen specializes in the fields of thrombosis, anesthesia, oncology, infectious diseases, and nervous system disorders. The various divisions of Aspen include Aspen Global Commercial, Aspen Pharmacare, Aspen Nutritionals, Aspen Oss, Aspen Business Europe, and Aspen Healthcare. Aspen Global Commercial is responsible for the sale of products in various regions of the world. Aspen Pharmacare is engaged in the production and sale of generics and branded drugs. Aspen Nutritionals produces dietary supplements and baby food. Aspen Oss manufactures and distributes bone substitute materials. Aspen Business Europe is responsible for product distribution in Europe, and Aspen Healthcare operates hospitals and health centers in South Africa. Aspen offers a variety of products, including anticoagulants, anesthetics, antibiotics, cancer drugs, HIV/AIDS medications, as well as dietary supplements and baby food. In the field of thrombosis, the company offers a wide range of anticoagulants, such as the active ingredients heparin, enoxaparin, and fondaparinux. In the field of oncology, Aspen produces drugs for the treatment of breast cancer, colon cancer, and lung cancer. Aspen's products are utilized by many different customers worldwide, including government agencies, hospitals, pharmacies, and retailers. Aspen places great emphasis on the quality of its products and has implemented a quality management system to ensure that the products meet the highest standards. In recent years, there have been controversies surrounding Aspen, particularly regarding drug pricing. In 2016, Aspen was fined €5.2 million by the European Commission for charging unreasonably high prices for cancer drugs in five European countries. Aspen has denied the allegations and announced plans to appeal the decision. Despite these controversies, Aspen remains an important player in the global pharmaceutical market. The company has a wide range of products and operates in various regions of the world. Aspen is committed to improving the health and well-being of people and continuously works to develop innovative and effective medications. Aspen Group is one of the most popular companies on Eulerpool.

ROE Details

Decoding Aspen Group's Return on Equity (ROE)

Aspen Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Aspen Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Aspen Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Aspen Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Aspen Group stock

Return on Equity (ROE) of Aspen Group is 10.46 % in 2026.

Return on Equity (ROE) of Aspen Group changed from 11.17 % to 10.46 %, representing a -6.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Aspen Group since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Aspen Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Aspen Group

All Key Metrics — Aspen Group